PRODUCT

GenesWell BCT

Multigene prognostic test for early breast cancer

What is multigene prognostic test?

Multigene prognostic test predicts the probability of metastasis or recurrence, which helps patients make treatment decision. It improves quality of life for cancer patients as preventing them from unnecessary chemotherapy.

GenesWell BCT

GenesWell BCT predicts probability of distant metastasis and chemobenefit within 10 years after surgery.

Target subtype

  • EARLY STAGE
  • ER+
  • PR+
  • HER2-
  • pN0/1

Process

  • Extract RNA from tumor tissue
  • Analyze expression level of prognostic genes related in breast cancer
  • Calculate risk using GenesWell BCT Algorithm
  • Provide results of risk classification and probability of distant metastasis

Detail